Secondary Navigation Menu

Audience Switcher Modal

Country and Audience Choose Modal

Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities.

Scientific Congress Publications

Supported by Bayer Pharmaceuticals

AHA 2026

Clinical Characteristics and Outcomes of Patients with Non-Cardioembolic Ischemic Stroke

In this nationwide observational cohort study of 1.5 million patients admitted for NCIS, the following was observed:

 

  1. Mild presenting deficits 

     

  2. Poor functional outcomes, as indicated by discharge location 

     

  3. Substantial post-acute care needs, particularly among patients with prior stroke 
Back to AHA 2026

© 2026 Bayer. All rights reserved.
Bayer and the Bayer Cross are registered trademarks of Bayer.

Copies of the Bayer Pharmaceuticals supported presentations obtained from this platform are for personal use only and may not be reproduced or distributed without permission from the authors.

Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities, and the presentations are shared in the interest of scientific exchange.

For any questions, please contact Medical Information at https://www.medicalinformation.bayer.com/

PP-GEN-ALL-0014-1